Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.

Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydr

Abstract: Phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. However, there is a problem that an amount of phytol to be taken for exhibiting cancer cell growth inhabition is large. A cancer cell growth inhibiting composition comprising at least one of compounds having a structure represented by Formula (1), Formula (2), Formula (6), Formula (7) or Formula (8), or a pharmaceutically acceptable salt thereof as main components has a higher cancer cell growth inhibiting effect than phytol.

Abstract: No drug has been available for treating a peripheral sensory neuropathy caused as a side effect by a drug, in particular, by an anticancer drug such as oxaliplatin. A composition for ameliorating peripheral sensory neuropathy, which is characterized by including a Lentinus edodes mycelium extract, ameliorates symptoms induced by the drug such as the anticancer drug, including numbness of extremities, a pain in extremities, a reduction in deep tendon reflection, a reduction in muscle force, allodynia, hyperalgesia, impaired finger fine movement, impaired walking, stumbling, falling, impaired flexion (being difficult or impossible to sit on one's heels, sit cross-legged, sit with one's legs out to one side, sit on a chair, or the like), or paralysis of extremities.

Abstract: A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.

Abstract: A nerve cell culture material including LASCol has the effect of successfully maintaining survival of the nerve cell. Furthermore, a therapeutic agent for nerve damage including LASCol can allow an endogenous nerve cell to infiltrate or proliferate actively in vivo, thereby enabling neurites to extend early and bind to each other, and has an effect on nerve damage, the effect being sufficient to improve a BBB score.

Abstract: Disclosed is a method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising: measuring a free protein marker in a liquid sample collected from a subject; and determining the efficacy of the immune checkpoint inhibitor in the subject based on a result of the measurement, wherein the free protein marker is at least one selected from free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).

Abstract: A so-called molecular-targeted drug acting on a signal transduction pathway in a cell has been developed. However, a side effect of the molecular-targeted drug is not negligible for a patient. Thus, there has been a demand for a substance that exhibits a significant growth inhibitory effect on a cancer cell with fewer side effects as a health food and a pharmaceutical composition. It has been found that a hexane extract fraction of a watermelon sprout has an effect of specifically inhibiting the cell growth of the cancer cell and such an effect is primarily caused by phytol and lutein. A processed food and pharmaceutical composition having these substances as main components can exert an anticancer action without causing side effects.

Abstract: A treatment method is capable of degrading or sterilizing harmful substances or microorganisms of which the degradation, detoxification, or the like is not easy for ozone gas alone. A harmful substance treatment method is one that makes ozone gas act on harmful substances, microorganisms, or the like in an environment humidified using a surfactant solution. The harmful substances include anticancer drugs. As a surfactant to be used, a non-ionic surfactant, an anionic surfactant, a cationic surfactant, or an amphoteric surfactant can be used.

Abstract: A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.

Abstract: A fluorene derivative represented by General Formula (1) below. X1—Y—X2??General Formula (1) In the General Formula (1), X1 represents a cyclic carbonate group including a carbonate bond [—O—C(?O)—O—], X2 represents a cyclic carbonate group including a carbonate bond [—O—C(?O)—O—], and Y represents a bivalent group including a 9,9-bisaryl fluorene skeleton.

Abstract: A CT value controller includes a storage means, an input means, and a computing means. The storage means stores a function expressing a relative humidity and a CT value regarding a degradation degree of an anticancer agent, an assumed relative humidity, and a CT setting. The input means inputs a measured relative humidity and a measured ozone concentration at a time of degradation treatment of the anticancer agent. The computing means calculates a corrected CT value increment based on a difference between the measured relative humidity and the assumed relative humidity at every input of the relative humidity and the ozone concentration by using the function. The computing means determines a termination of the degradation treatment of the anticancer agent when an integrated CT value of the corrected CT value increments reaches the CT setting.

Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.

Abstract: The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action.

Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.

Abstract: [Problem] To provide a therapeutic agent and a therapeutic method for EGFR-TKI-resistant non-small cell lung cancer. [Solution] Provided are: a therapeutic agent that contains an anti-HER3 antibody-drug conjugate as an active ingredient, or a therapeutic method characterized by administering an anti-HER3 antibody-drug conjugate.

Abstract: The present invention provides a method for producing a carbon nanotube sheet that is excellent in light transmittance and conductivity, and the carbon nanotube sheet. The method includes firstly modifying of modifying a free-standing unmodified carbon nanotube sheet in which a plurality of carbon nanotubes are aligned in a predetermined direction. The firstly modifying includes performing a densification process of bringing the unmodified carbon nanotube sheet into contact with either one of or both of vapor and liquid particles of a liquid substance to produce a modified carbon nanotube sheet that contains the carbon nanotubes which are mainly aligned in a predetermined direction, and that includes a high density portion where the carbon nanotubes are assembled together and a low density portion where density of the carbon nanotubes is relatively lower than density in the high density portion.

Abstract: No drug has been available for treating a peripheral sensory neuropathy caused as a side effect by a drug, in particular, by an anticancer drug such as oxaliplatin. A composition for ameliorating peripheral sensory neuropathy, which is characterized by including a Lentinus edodes mycelium extract, ameliorates symptoms induced by the drug such as the anticancer drug, including numbness of extremities, a pain in extremities, a reduction in deep tendon reflection, a reduction in muscle force, allodynia, hyperalgesia, impaired finger fine movement, impaired walking, stumbling, falling, impaired flexion (being difficult or impossible to sit on one's heels, sit cross-legged, sit with one's legs out to one side, sit on a chair, or the like), or paralysis of extremities.

Abstract: Provided are a novel cultivation method and a storage method that are suitable for storing bacteria belonging to the genus Collimonas for a long period of time. The cultivation method for bacteria belonging to the genus Collimonas is characterized in that bacteria belonging to the genus Collimonas are cultivated in a sealed state on a culture medium that includes a rice bran culture medium and/or a soy pulp culture medium. The storage method for bacteria belonging to the genus Collimonas is characterized in that the cultivated bacteria belonging to the genus Collimonas are stored at room temperature.

Abstract: A so-called molecular-targeted drug acting on a signal transduction pathway in a cell has been developed. However, a side effect of the molecular-targeted drug is not negligible for a patient. Thus, there has been a demand for a substance that exhibits a significant growth inhibitory effect on a cancer cell with fewer side effects as a health food and a pharmaceutical composition. It has been found that a hexane extract fraction of a watermelon sprout has an effect of specifically inhibiting the cell growth of the cancer cell and such an effect is primarily caused by phytol and lutein. A processed food and pharmaceutical composition having these substances as main components can exert an anticancer action without causing side effects.